Alzheimer's disease vaccine - Elan

Drug Profile

Alzheimer's disease vaccine - Elan

Alternative Names: AIP 001; Amyloid-beta42 vaccine - Elan; AN-1792; AN-1792/QS-21; Aβ42 vaccine; Betabloc

Latest Information Update: 27 Oct 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elan Pharmaceuticals
  • Developer Elan Pharmaceuticals; Wyeth
  • Class Vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 26 Jul 2007 Discontinued - Phase-II for Alzheimer's disease in USA (Parenteral)
  • 28 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to the Alzheimer's Disease and Cognition Disorders therapeutic trials section
  • 27 Nov 2003 Data presented at the 33rd Annual Meeting of the Society of Neuroscience (AMSN-2003) have been added to the Alzheimer's Disease and Cognition Disorders immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top